![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Cipla Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Nateglinide, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2015-308 - Rev 00
This Chemical Type CEP, issued on June 08, 2017, remains in force until September 08, 2020, ensuring its reliability within the pharmaceutical industry.
Substance Number 2575 associated with this CEP further emphasizes